{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:55:53Z","timestamp":1794851753395,"version":"4.9.1"},"reference-count":131,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Adeno-associated virus (AAV)\u2013based gene therapy is an emerging treatment for hemophilia A (HA) and hemophilia B (HB). In this systematic review and meta-analysis, we searched for studies of adult males with severe or moderately severe HA or HB who received AAV-based gene therapy. Annualized bleeding rate (ABR), annualized infusion rate (AIR), total factor use, factor levels, and adverse events (AEs) were extracted. Eight HA trials representing 7 gene therapies and 211 patients and 12 HB trials representing 9 gene therapies and 184 patients were included. For HA, gene therapy resulted in an annualized decrease of 7.58 bleeding events (95% confidence interval [CI],\u00a0\u221211.50 to\u00a0\u22123.67) and 117.2 factor infusions (95%\u00a0CI,\u00a0\u2212151.86 to\u00a0\u221282.53) compared with before gene therapy. Factor VIII level at 12\u00a0months ranged from 10.4 to 70.31 IU\/mL by 1-stage assay. HB gene therapies were associated with an annualized decrease of 5.64 bleeding events (95%\u00a0CI,\u00a0\u22128.61 to\u00a0\u22122.68) and 58.92 factor infusions (95%\u00a0CI,\u00a0\u221268.19 to\u00a0\u221249.65). Mean factor IX level at 12\u00a0months was 28.72 IU\/mL (95%\u00a0CI, 18.78-38.66). Factor expression was more durable for HB than HA; factor IX levels remained at 95.7% of their peak whereas factor VIII levels fell to 55.8% of their peak at 24\u00a0months. The pooled percentage of patients experiencing a serious AE was 19% (10%-31%) and 21% (10%-37%) for HA and HB gene therapies, respectively. No thrombosis or inhibitor formation was reported. AAV-based gene therapies for both HA and HB demonstrated significant reductions in ABR, AIR, and factor use.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014111","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T21:59:46Z","timestamp":1728338386000},"page":"5957-5974","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Adeno-associated virus\u2013based gene therapy for hemophilia A and B: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9824-9052","authenticated-orcid":false,"given":"Saarang R.","family":"Deshpande","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-7625","authenticated-orcid":false,"given":"Keerthy","family":"Joseph","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, St. Luke\u2019s University Hospital, Easton, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1213-6699","authenticated-orcid":false,"given":"Jiayi","family":"Tong","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0835-0788","authenticated-orcid":false,"given":"Yong","family":"Chen","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9997-454X","authenticated-orcid":false,"given":"Allyson","family":"Pishko","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"4Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"8","key":"2024121014513333500_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"issue":"suppl 6","key":"2024121014513333500_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition [published correction appears in Haemophilia. 2021;27(4):699]","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"7","key":"2024121014513333500_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0032-1326786","article-title":"The diagnosis and management of congenital hemophilia","volume":"38","author":"Carcao","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"2024121014513333500_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024121014513333500_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024121014513333500_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2024121014513333500_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024121014513333500_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024121014513333500_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","article-title":"Fidanacogene elaparvovec: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"2024121014513333500_bib10","author":"Deshpande","year":"2023"},{"issue":"8284","key":"2024121014513333500_bib11","first-page":"1-36","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"2024121014513333500_bib12","author":"National Institute of Health","year":"2021"},{"issue":"2","key":"2024121014513333500_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/biostatistics\/kxt046","article-title":"A\u00a0model-based correction for outcome reporting bias in meta-analysis","volume":"15","author":"Copas","year":"2014","journal-title":"Biostatistics"},{"issue":"7414","key":"2024121014513333500_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"2024121014513333500_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"issue":"8","key":"2024121014513333500_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2307\/1175260","article-title":"Summing up: the science of reviewing research","volume":"15","author":"Light","year":"1986","journal-title":"Educ Res"},{"issue":"7109","key":"2024121014513333500_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"suppl 1","key":"2024121014513333500_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood-2018-99-118050","article-title":"A\u00a0single intravenous infusion of FLT180a results in factor IX activity levels of more than 40% and has the potential to provide a functional cure for patients with haemophilia B","volume":"132","author":"Chowdary","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2024121014513333500_bib19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/rth2.12310","article-title":"A\u00a0novel adeno associated virus (AAV) gene therapy (FLT180a) achieves normal FIX activity levels in severe hemophilia B (HB) patients (B-AMAZE Study)","volume":"4","author":"Chowdary","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2024121014513333500_bib20","author":"Chowdary","year":"3  2021"},{"issue":"suppl 1","key":"2024121014513333500_bib21","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1182\/blood-2021-146546","article-title":"Factor IX expression within the normal range prevents spontaneous bleeds requiring treatment following FLT180a gene therapy in patients with severe hemophilia B: long-term follow-up study of the B-Amaze program","volume":"138","author":"Chowdary","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024121014513333500_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024121014513333500_bib23","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2023-180803","article-title":"GO-8: stable expression of factor VIII over 5 years following adeno-associated gene transfer in subjects with hemophilia A using a novel human factor VIII variant","volume":"142","author":"Chowdary","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024121014513333500_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024121014513333500_bib25","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood-2022-158903","article-title":"Long-term durable FVIII expression with improvements in bleeding rates following AAV-mediated FVIII gene transfer for hemophilia A: multiyear follow-up on the phase I\/II trial of SPK-8011","volume":"140","author":"Croteau","year":"2022","journal-title":"Blood"},{"key":"2024121014513333500_bib26","author":"Cuker","year":"24  2023"},{"issue":"21","key":"2024121014513333500_bib27","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood.V120.21.752.752","article-title":"Stable factor IX activity following AAV-mediated gene transfer in patients with severe hemophilia B","volume":"120","author":"Davidoff","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2024121014513333500_bib28","first-page":"e567","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Due","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024121014513333500_bib29","doi-asserted-by":"crossref","first-page":"10656","DOI":"10.1182\/blood-2022-163297","article-title":"BAX 335 hemophilia B gene therapy phase 1\/2 clinical trial: long-term safety and efficacy follow-up","volume":"140","author":"Escobar","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2024121014513333500_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V128.22.3.3","article-title":"Spk-9001: adeno-associated virus mediated gene transfer for hemophilia B achieves sustained mean factor IX activity levels of &gt;30% without immunosuppression","volume":"128","author":"George","year":"2016","journal-title":"Blood"},{"issue":"S3","key":"2024121014513333500_bib31","first-page":"33","article-title":"Preliminary results of a phase 1\/2 trial of SPK-9001, a hyperactive FIX variant delivered by a novel capsid, demonstrate consistent factor IX activity levels at the lowest dose cohort","volume":"22","author":"George","year":"2016","journal-title":"Haemophilia"},{"issue":"S1","key":"2024121014513333500_bib32","first-page":"604","article-title":"SPK-8011: preliminary results from a phase 1\/2 dose escalation trial of an investigational AAV-mediated gene therapy for hemophilia A","volume":"130","author":"George","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2024121014513333500_bib33","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"S1","key":"2024121014513333500_bib34","first-page":"601","article-title":"Spk-9001: adeno-associated virus mediated gene transfer for hemophilia B - 1 year follow up and impact of baseline characteristics on transgene-derived factor IX activity and persistence","volume":"130","author":"George","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib35","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2019-124091","article-title":"Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year","volume":"134","author":"George","year":"2019","journal-title":"Blood"},{"issue":"S1","key":"2024121014513333500_bib36","first-page":"10","article-title":"Phase I\/II trial of SPK-8011: stable and durable FVIII expression for &gt;2 years with significant ABR improvements in initial dose cohorts following AAV-mediated FVIII gene transfer for hemophilia A","volume":"4","author":"George","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"2024121014513333500_bib37","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"issue":"21","key":"2024121014513333500_bib38","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"S2","key":"2024121014513333500_bib39","first-page":"92","article-title":"Phase I\/II trial of SPK-8011: stable and durable FVIII expression after AAV gene transfer for hemophilia A","volume":"5","author":"George","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"S2","key":"2024121014513333500_bib40","first-page":"405","article-title":"Evaluation of liver health after fidanacogene elaparvovec gene therapy: data from study participants with up to 5 years of follow-up","volume":"5","author":"George","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2024121014513333500_bib41","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1182\/blood-2022-159421","article-title":"Updated results of the Alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia A","volume":"140","author":"Giermasz","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"2024121014513333500_bib42","first-page":"487","article-title":"Etranacogene dezaparvovec (AAV5-Padua hFIX Variant, AMT-061), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B: 2.5 year data from a phase 2b trial","volume":"5","author":"Gomez","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2024121014513333500_bib43","author":"Harrington","year":"11  2023"},{"issue":"suppl 1","key":"2024121014513333500_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2018-99-115495","article-title":"A\u00a0phase 1\/2 trial of investigational SPK-8011 in hemophilia A demonstrates durable expression and prevention of bleeds","volume":"132","author":"High","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"2024121014513333500_bib45","first-page":"2056","article-title":"Spk-9001: adeno-associated virus mediated gene transfer for hemophilia B achieves sustained factor IX with minimal immune response","volume":"130","author":"Hui","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2024121014513333500_bib46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/hae.14977","article-title":"Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: results from the phase III HOPE-B trial 2 years after gene therapy","volume":"30","author":"Itzler","year":"2024","journal-title":"Haemophilia"},{"key":"2024121014513333500_bib47","author":"Itzler","year":"9  2022"},{"key":"2024121014513333500_bib48","author":"Itzler","year":"24  2023"},{"issue":"1","key":"2024121014513333500_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hae.14882","article-title":"Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B","volume":"30","author":"Klamroth","year":"2024","journal-title":"Haemophilia"},{"key":"2024121014513333500_bib50","author":"Konkle","year":"6  2019"},{"issue":"suppl 1","key":"2024121014513333500_bib51","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2019-122143","article-title":"Updated follow-up of the Alta study, a phase 1\/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult patients with severe hemophilia A","volume":"134","author":"Konkle","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2024121014513333500_bib52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"2024121014513333500_bib53","author":"Laffan","year":"9  2022"},{"issue":"suppl 1","key":"2024121014513333500_bib54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-137648","article-title":"Updated follow-up of the Alta study, a phase 1\/2 study of giroctocogene fitelparvovec (SB-525) gene therapy in adults with severe hemophilia A","volume":"136","author":"Leavitt","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2024121014513333500_bib55","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"issue":"22","key":"2024121014513333500_bib56","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1182\/blood.V128.22.2314.2314","article-title":"Interim results from a dose escalating study of AMT-060 (AAV5-hFIX) gene transfer in adult patients with severe hemophilia B","volume":"128","author":"Leebeek","year":"2016","journal-title":"Blood"},{"issue":"S1","key":"2024121014513333500_bib57","first-page":"602","article-title":"Stable elevations in FIX activity and reductions in annualized bleeding rate over up to 2 years of follow-up of adults with severe or moderate-severe hemophilia B treated with AMT-060 (AAV5-hFIX) gene therapy","volume":"130","author":"Leebeek","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib58","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1182\/blood-2018-99-109995","article-title":"Reduction in annualized bleeding and factor IX consumption up to 2.5 years in adults with severe or moderate-severe hemophilia B treated with AMT-060 (AAV5-hFIX) gene therapy","volume":"132","author":"Leebeek","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139225","article-title":"AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B confirm stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 5 years","volume":"136","author":"Leebeek","year":"2020","journal-title":"Blood"},{"issue":"S2","key":"2024121014513333500_bib60","first-page":"92","article-title":"Clinical outcomes in adults with hemophilia B with and without pre-existing neutralizing antibodies to AAV5: 6 month data from the phase 3 etranacogene dezaparvovec HOPE-B gene therapy trial","volume":"5","author":"Leebeek","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"S1","key":"2024121014513333500_bib61","first-page":"4611","article-title":"Interim analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in a phase-1\/2 clinical study of BMN 270, an AAV5-mediated gene therapy for hemophilia A","volume":"130","author":"Long","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024121014513333500_bib62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"},{"issue":"7","key":"2024121014513333500_bib63","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024121014513333500_bib64","author":"Mahlangu","year":"21  2023"},{"issue":"9","key":"2024121014513333500_bib65","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib66","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood-2019-122535","article-title":"Stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 4 years following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B","volume":"134","author":"Miesbach","year":"2019","journal-title":"Blood"},{"issue":"S2","key":"2024121014513333500_bib67","first-page":"90","article-title":"Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following amt-060 gene therapy in adults with severe or moderate-severe hemophilia B","volume":"5","author":"Miesbach","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2024121014513333500_bib68","author":"Miesbach","year":"2  2022"},{"issue":"suppl 1","key":"2024121014513333500_bib69","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/blood-2022-166810","article-title":"Durability of factor IX activity and bleeding rate in people with severe or moderately severe hemophilia B after 5 years of follow-up in the phase 1\/2 study of AMT-060, and after 3 years of follow-up in the phase 2b and 2 years of follow-up in the phase 3 studies of etranacogene dezaparvovec (AMT-061)","volume":"140","author":"Miesbach","year":"2022","journal-title":"Blood"},{"issue":"S1","key":"2024121014513333500_bib70","first-page":"46","article-title":"Durability of factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1\/2 study of AMT-060, and phase 2b and phase 3 studies of etranocogene dezaparvovec (AMT-061)","volume":"43","author":"Miesbach","year":"2023","journal-title":"H\u00e4mostaseologie"},{"issue":"S1","key":"2024121014513333500_bib71","first-page":"80","article-title":"Long-term FVIII expression with reduced bleeding following gene transfer for hemophilia A: follow-up on the dirloctocogene samoparvovec phase I\/II trial","volume":"44","author":"Miesbach","year":"2024","journal-title":"H\u00e4mostaseologie"},{"issue":"25","key":"2024121014513333500_bib72","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024121014513333500_bib73","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024121014513333500_bib74","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","article-title":"GO-8: preliminary results of a phase I\/II dose escalation trial of gene therapy for hemophilia A using a novel human factor VIII variant","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing \"empty viral particles\" on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2024121014513333500_bib76","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jtha.2023.08.032","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1","volume":"21","author":"O\u2019Mahony","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"suppl 1","key":"2024121014513333500_bib77","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2021-146021","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1","volume":"138","author":"O'Mahony","year":"2021","journal-title":"Blood"},{"key":"2024121014513333500_bib78","author":"O\u2019Mahony","year":"2  2022"},{"issue":"S2","key":"2024121014513333500_bib79","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.htct.2020.10.099","article-title":"A\u00a0first in-human four-year follow-up study of durable therapeutic efficacy and safety of AAV gene therapy with valoctocogene roxaparvovec for severe hemophilia A","volume":"42","author":"Ozelo","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"2024121014513333500_bib80","author":"Ozelo","year":"17  2021"},{"issue":"S4","key":"2024121014513333500_bib81","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.htct.2023.09.842","article-title":"Bleeding, FVIII activity, and safety 3 years after gene transfer with valoctocogene roxaparvovec: results from Gener8-1","volume":"45","author":"Ozelo","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"2024121014513333500_bib82","author":"Pasi","year":"10  2017"},{"issue":"S1","key":"2024121014513333500_bib83","first-page":"603","article-title":"Achievement of normal circulating factor VIII activity following BMN 270 AAV5-FVIII gene transfer: interim, long term efficacy and safety results from a phase 1\/2 study in patients with severe hemophilia a","volume":"130","author":"Pasi","year":"2017","journal-title":"Blood"},{"key":"2024121014513333500_bib84","author":"Pasi","year":"8  2019"},{"issue":"1","key":"2024121014513333500_bib85","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"2024121014513333500_bib86","author":"Pasi","year":"17  2021"},{"issue":"6","key":"2024121014513333500_bib87","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"issue":"S1","key":"2024121014513333500_bib88","first-page":"3331","article-title":"Single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate\/severe hemophilia B that demonstrated meaningful but transient expression of human factor IX (hFIX)","volume":"130","author":"Pipe","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib89","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2019-125764","article-title":"First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A","volume":"134","author":"Pipe","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib90","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2019-128765","article-title":"One year data from a phase 2b trial of AMT-061 (AAV5-padua hfix variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B","volume":"134","author":"Pipe","year":"2019","journal-title":"Blood"},{"key":"2024121014513333500_bib91","author":"Pipe","year":"14  2020"},{"issue":"suppl 2","key":"2024121014513333500_bib92","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood-2020-143560","article-title":"First data from the phase 3 HOPE-B gene therapy trial: efficacy and safety of etranacogene dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in adults with severe or moderate-severe hemophilia B treated irrespective of pre-existing anti-capsid neutralizing antibodies","volume":"136","author":"Pipe","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib93","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-139803","article-title":"First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A - BAY 2599023 has broad patient eligibility and stable and sustained long-term expression of FVIII","volume":"136","author":"Pipe","year":"2020","journal-title":"Blood"},{"issue":"S1","key":"2024121014513333500_bib94","first-page":"27","article-title":"First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A: safety and FVIII activity results","volume":"4","author":"Pipe","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2024121014513333500_bib95","author":"Pipe","year":"3  2021"},{"key":"2024121014513333500_bib96","author":"Pipe","year":"9  2021"},{"key":"2024121014513333500_bib97","author":"Pipe","year":"17  2021"},{"issue":"S2","key":"2024121014513333500_bib98","first-page":"490","article-title":"Evolution of AAV vector gene therapy is ongoing in hemophilia. Will the unique features of BAY 2599023 address the outstanding needs?","volume":"5","author":"Pipe","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2024121014513333500_bib99","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1182\/blood-2021-148661","article-title":"First-in-human dose-finding study of AAVhu37 vector-based gene therapy: BAY 2599023 has stable and sustained expression of FVIII over 2 years","volume":"138","author":"Pipe","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib100","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2021-144508","article-title":"Relationship between endogenous, transgene FVIII expression and bleeding events following valoctocogene roxaparvovec gene transfer for severe hemophilia A: a post-hoc analysis of the GENEr8-1 phase 3 trial","volume":"138","author":"Pipe","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib101","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1182\/blood-2022-166135","article-title":"Adults with severe or moderately severe hemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 clinical trial continue to experience a stable increase in mean Factor IX activity levels and durable hemostatic protection after 24\u00a0months\u2019 follow-up","volume":"140","author":"Pipe","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib102","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1182\/blood-2022-166745","article-title":"Durability of bleeding protection and factor IX activity levels are demonstrated in individuals with and without adeno-associated virus serotype 5 neutralizing antibodies (titers &lt;1:700) with comparable safety in the phase 3 HOPE-B clinical trial of etranacogene dezaparvovec gene therapy for hemophilia B","volume":"140","author":"Pipe","year":"2022","journal-title":"Blood"},{"key":"2024121014513333500_bib103","author":"Pipe","year":"24  2023"},{"issue":"suppl 1","key":"2024121014513333500_bib104","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood-2023-187624","article-title":"Long-term bleeding protection, sustained FIX activity, reduction of FIX consumption and safety of hemophilia B gene therapy: results from the HOPE-B trial 3 years after administration of a single dose of etranacogene dezaparvovec in adult patients with severe or moderately severe hemophilia B","volume":"142","author":"Pipe","year":"2023","journal-title":"Blood"},{"issue":"S1","key":"2024121014513333500_bib105","first-page":"35","article-title":"Etranacogene dezaparvovec shows sustained efficacy and safety in adult patients with severe or moderately severe haemophilia B 3 years after administration in the HOPE-B trial","volume":"44","author":"Pipe","year":"2024","journal-title":"H\u00e4mostaseologie"},{"key":"2024121014513333500_bib106","author":"Ragni","year":"25  2023"},{"issue":"26","key":"2024121014513333500_bib107","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024121014513333500_bib108","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2023-186891","article-title":"Stable therapeutic transgenic FIX levels for more than 10 years in subjects with severe hemophilia B who received scAAV2\/8-LP1-Hfixco adeno-associated virus gene therapy","volume":"142","author":"Reiss","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib109","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood-2021-150541","article-title":"Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy","volume":"138","author":"Samelson-Jones","year":"2021","journal-title":"Blood"},{"key":"2024121014513333500_bib110","author":"Samelson-Jones","year":"25  2023"},{"key":"2024121014513333500_bib111","author":"Skinner","year":"25  2023"},{"issue":"2","key":"2024121014513333500_bib112","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"2024121014513333500_bib113","first-page":"129","article-title":"SPK-8016: preliminary results from a phase 1\/2 clinical trial of gene therapy for hemophilia A [abstract]","volume":"27","author":"Sullivan","year":"2021","journal-title":"Haemophilia"},{"key":"2024121014513333500_bib114","author":"Sullivan","year":"11  2016"},{"issue":"suppl 4","key":"2024121014513333500_bib115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2516.2012.02823.x","article-title":"Gene therapy for haemophilia B","volume":"18","author":"Tuddenham","year":"2012","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"2024121014513333500_bib116","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2021-148651","article-title":"Updated results of the Alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia A","volume":"138","author":"Visweshwar","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121014513333500_bib117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139295","article-title":"Etranacogene dezaparvovec (AAV5-Padua hFIX variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B: two year data from a phase 2b trial","volume":"136","author":"von Drygalski","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2024121014513333500_bib118","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"2024121014513333500_bib119","author":"von Mackensen","year":"11  2017"},{"key":"2024121014513333500_bib120","author":"von Mackensen","year":"6  2019"},{"issue":"suppl 1","key":"2024121014513333500_bib121","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2023-179431","article-title":"Health-related quality of life in adults with hemophilia B after receiving gene therapy with fidanacogene elaparvovec","volume":"142","author":"von Mackensen","year":"2023","journal-title":"Blood"},{"key":"2024121014513333500_bib122","author":"Yamaguti-Hayakawa","year":"25  2023"},{"key":"2024121014513333500_bib123","author":"Young","year":"24  2023"},{"issue":"3","key":"2024121014513333500_bib124","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"18","key":"2024121014513333500_bib125","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.2021010864","article-title":"The cost-effectiveness of gene therapy for severe hemophilia B: microsimulation study from the United States Perspective","volume":"138","author":"Bolous","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024121014513333500_bib126","first-page":"1-12","article-title":"Discussing investigational AAV gene therapy with hemophilia patients: a guide","volume":"47","author":"Sidonio","year":"2021","journal-title":"Blood Rev"},{"issue":"11","key":"2024121014513333500_bib127","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"issue":"3-4","key":"2024121014513333500_bib128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/hum.2023.208","article-title":"Efficacy and safety of adeno-associated virus-based clinical gene therapy for hemophilia: a systematic review and meta-analysis","volume":"35","author":"Han","year":"2024","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2024121014513333500_bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-9-10","article-title":"Overstating the evidence: double counting in meta-analysis and related problems","volume":"9","author":"Senn","year":"2009","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2024121014513333500_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/102453312X13221316477372","article-title":"Beyond patient benefit: clinical development in hemophilia","volume":"17","author":"Auerswald","year":"2012","journal-title":"Hematology"},{"key":"2024121014513333500_bib131","author":"Beasley","year":"2023"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/5957\/2345040\/blooda_adv-2024-014111-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/5957\/2345040\/blooda_adv-2024-014111-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:52:34Z","timestamp":1733842354000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/5957\/518100\/Adeno-associated-virus-based-gene-therapy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":131,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014111","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}